Árpád Patai

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

Lóránt Gönczi, K Gecse, Zsuzsanna Végh et al. · Inflammatory Bowel Diseases · 2017 · 57 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas

Árpád V. Patai, Árpád V. Patai, Gábor Valcz et al. · PLoS ONE · 2015 · 48 citations · Full text

Medicine, Molecular Biology, Oncology +17

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Lóránt Gönczi, Zsuzsanna Végh, Petra A. Golovics et al. · Journal of Crohn s and Colitis · 2016 · 48 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

Anita Bálint, Mariann Rutka, Zsuzsanna Végh et al. · Expert Opinion on Drug Safety · 2017 · 28 citations

Medicine, Immunology, Pharmacology +15

ERCP is more challenging in cases of acute biliary pancreatitis than in acute cholangitis – Analysis of the Hungarian ERCP registry data

Dániel Pécsi, Szilárd Gódi, Péter Hegyi et al. · Pancreatology · 2020 · 19 citations · Full text

Medicine, Radiology, Gastroenterology +16